CORRECTION -- Precipio continues to sign up and onboard HemeScreen™ customers
07. März 2023 12:49 ET
|
Precipio, Inc.
NEW HAVEN, Conn., March 07, 2023 (GLOBE NEWSWIRE) -- In a release issued under the same headline earlier today by Precipio, Inc. (NASDAQ: PRPO), please note that the 5th paragraph should read...
Precipio continues to sign up and onboard HemeScreen™ customers
07. März 2023 12:00 ET
|
Precipio, Inc.
NEW HAVEN, Conn., March 07, 2023 (GLOBE NEWSWIRE) -- Specialty cancer diagnostics company Precipio, Inc. (NASDAQ: PRPO) continues to convert its sales pipeline into HemeScreen customers, with an...
Precipio Signs Another Major HemeScreen™ Customer
11. Januar 2023 10:00 ET
|
Precipio, Inc.
NEW HAVEN, Conn., Jan. 11, 2023 (GLOBE NEWSWIRE) -- Specialty cancer diagnostics company Precipio, Inc. (NASDAQ: PRPO) announced another 4-year agreement with a new customer to bring HemeScreen™...
Precipio to distribute HemeScreen® through Fisher Healthcare channel
20. Juli 2022 10:30 ET
|
Precipio, Inc.
NEW HAVEN, Conn., July 20, 2022 (GLOBE NEWSWIRE) -- Specialty cancer diagnostics company Precipio, Inc. (NASDAQ: PRPO), today announced that it has entered into an agreement with Fisher Healthcare,...
Precipio customer American Oncology Network (AON) selected to present HemeScreen® technology case study at Industry leading clinical laboratory conference
26. April 2022 10:00 ET
|
Precipio, Inc.
NEW HAVEN, Conn., April 26, 2022 (GLOBE NEWSWIRE) -- Specialty cancer diagnostics company Precipio, Inc. (NASDAQ: PRPO), is excited to announce its participation and the presentation of HemeScreen,...
New York State Approves Precipio’s HemeScreen for POL clinical use
18. November 2021 10:00 ET
|
Precipio, Inc.
NEW HAVEN, Conn., Nov. 18, 2021 (GLOBE NEWSWIRE) -- Specialty cancer diagnostics company Precipio, Inc. (NASDAQ: PRPO) announces that its HemeScreen RUO assay has received the required approval from...
American Oncology Network Partners with Precipio to Bring HemeScreen® into AON’s Laboratory
26. August 2021 10:00 ET
|
Precipio, Inc.
NEW HAVEN, Conn. and FORT MYERS, Fla., Aug. 26, 2021 (GLOBE NEWSWIRE) -- Specialty cancer diagnostics company Precipio, Inc. (NASDAQ: PRPO), and American Oncology Network, LLC (AON), a high-growth...
Current Signed Customers Expected to Generate $1M Annualized Reported Revenues from Precipio’s HemeScreen POL Offering by Q4-2021
26. April 2021 11:00 ET
|
Precipio, Inc.
NEW HAVEN, Conn., April 26, 2021 (GLOBE NEWSWIRE) -- Specialty diagnostics company Precipio, Inc. (NASDAQ: PRPO), announced that currently, the contracted annualized revenues from signed customers...
Precipio Signs HemeScreen™ Deals with Two Leading Oncology Groups
20. Januar 2021 10:00 ET
|
Precipio, Inc.
NEW HAVEN, Conn., Jan. 20, 2021 (GLOBE NEWSWIRE) -- Specialty cancer diagnostics company Precipio, Inc. (NASDAQ: PRPO) has signed agreements with two of the largest oncology practices in the US,...
Precipio Signs Sales & Marketing Agreement for HemeScreen™ with Major Oncology Distributor
10. Dezember 2020 10:15 ET
|
Precipio, Inc.
NEW HAVEN, Conn., Dec. 10, 2020 (GLOBE NEWSWIRE) -- Specialty cancer diagnostics company Precipio, Inc. (NASDAQ: PRPO) has entered into an agreement with a major US-based oncology distributor to...